JP2021100937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021100937A5 JP2021100937A5 JP2021031431A JP2021031431A JP2021100937A5 JP 2021100937 A5 JP2021100937 A5 JP 2021100937A5 JP 2021031431 A JP2021031431 A JP 2021031431A JP 2021031431 A JP2021031431 A JP 2021031431A JP 2021100937 A5 JP2021100937 A5 JP 2021100937A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- equation
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 206010008723 Chondrodystrophy Diseases 0.000 claims 2
- 208000008919 achondroplasia Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000020221 Short stature Diseases 0.000 claims 1
- 230000022159 cartilage development Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16150624.1 | 2016-01-08 | ||
| EP16150624 | 2016-01-08 | ||
| EP16179286 | 2016-07-13 | ||
| EP16179286.6 | 2016-07-13 | ||
| EP16191458 | 2016-09-29 | ||
| EP16191458.5 | 2016-09-29 | ||
| JP2018535304A JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535304A Division JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021100937A JP2021100937A (ja) | 2021-07-08 |
| JP2021100937A5 true JP2021100937A5 (enExample) | 2021-08-26 |
| JP6951597B2 JP6951597B2 (ja) | 2021-10-20 |
Family
ID=57838356
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535304A Active JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2021031431A Active JP6951597B2 (ja) | 2016-01-08 | 2021-03-01 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2022054845A Active JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2023147381A Active JP7692454B2 (ja) | 2016-01-08 | 2023-09-12 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535304A Active JP7051686B2 (ja) | 2016-01-08 | 2017-01-05 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022054845A Active JP7350123B2 (ja) | 2016-01-08 | 2022-03-30 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
| JP2023147381A Active JP7692454B2 (ja) | 2016-01-08 | 2023-09-12 | 大型のキャリアー部分を有するｃｎｐプロドラッグ |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US10835578B2 (enExample) |
| EP (1) | EP3400020A1 (enExample) |
| JP (4) | JP7051686B2 (enExample) |
| AU (2) | AU2017205268B2 (enExample) |
| CA (1) | CA3007976C (enExample) |
| MX (1) | MX2018008061A (enExample) |
| WO (1) | WO2017118693A1 (enExample) |
| ZA (1) | ZA201804414B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017118703A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
| US10835578B2 (en) | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
| WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| IL259829B2 (en) * | 2016-01-08 | 2023-03-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr–c binding |
| WO2017118698A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| CN108472380B (zh) | 2016-01-08 | 2022-03-01 | 阿森迪斯药物生长障碍股份有限公司 | 具有增加的nep稳定性的控制释放cnp激动剂 |
| EP4223309A1 (en) | 2016-09-29 | 2023-08-09 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
| EP4011396A1 (en) | 2017-03-10 | 2022-06-15 | QuiaPEG Pharmaceuticals AB | Releasable conjugates |
| CA3093722A1 (en) * | 2018-03-28 | 2019-10-03 | Ascendis Pharma Oncology Division A/S | Il-2 conjugates |
| TWI834720B (zh) | 2018-09-12 | 2024-03-11 | 瑞典商奎亞培格製藥公司 | 可釋放glp-1共軛物 |
| MX2021008708A (es) | 2019-02-11 | 2021-09-21 | Ascendis Pharma Growth Disorders As | Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp). |
| US12428461B2 (en) | 2020-06-03 | 2025-09-30 | Ascendis Pharma Oncology Division A/S | Treating cancer with a conjugate comprising an IL-2 moiety |
| US20230241164A1 (en) * | 2020-06-12 | 2023-08-03 | Hirofumi Tachibana | C-Type Natriuretic Peptides and Methods Thereof in Treating Cancer |
| WO2023110758A1 (en) * | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| JP2025522281A (ja) * | 2022-05-23 | 2025-07-15 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | Ｃｎｐ化合物の液体医薬製剤 |
| US12077561B2 (en) | 2022-11-02 | 2024-09-03 | Novo Nordisk A/S | CNP compounds |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| WO2000018422A1 (fr) | 1998-09-28 | 2000-04-06 | Santen Pharmaceutical Co., Ltd. | Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite |
| ES2556338T3 (es) | 2001-10-10 | 2016-01-15 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US8596542B2 (en) * | 2002-06-04 | 2013-12-03 | Hand Held Products, Inc. | Apparatus operative for capture of image data |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| AU2003297583B2 (en) * | 2002-11-26 | 2010-01-14 | Biocon, Ltd | Modified naturetic compounds, conjugates, and uses thereof |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| ES2741524T3 (es) | 2004-03-23 | 2020-02-11 | Ascendis Pharma Gmbh | Profármaco polimérico con un enlazador autoinmolador |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| WO2008031045A2 (en) | 2006-09-08 | 2008-03-13 | Mayo Foundation For Medical Education And Research | Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
| MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| US8632809B2 (en) | 2006-11-09 | 2014-01-21 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
| CA2684468C (en) * | 2007-04-20 | 2016-01-12 | Shell Internationale Research Maatschappij B.V. | Varying properties of in situ heat treatment of a tar sands formation based on assessed viscosities |
| KR20080098216A (ko) | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| EP2369005B1 (en) | 2007-06-21 | 2013-04-03 | Technische Universität München | Biological active proteins having increased in vivo and/or in vitro stability |
| CA2693616A1 (en) | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| EP2217620A2 (en) | 2007-11-21 | 2010-08-18 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| JP5588354B2 (ja) | 2008-02-01 | 2014-09-10 | アセンディス ファーマ エー／エス | 自己切断可能なリンカーを含むプロドラッグ |
| TW201004648A (en) | 2008-05-23 | 2010-02-01 | Enzon Pharmaceuticals Inc | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| WO2010033217A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of cd-np peptides |
| KR101544245B1 (ko) | 2009-02-03 | 2015-08-12 | 아뮤닉스 오퍼레이팅 인코포레이티드 | 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물 |
| BRPI1012783B1 (pt) | 2009-05-20 | 2021-09-21 | Biomarin Pharmaceutical Inc | Variantes de peptídeo natriurético tipo c (cnp), seu método de produção recombinante e seu uso, composição farmacêutica e composição para tratamento de uma condição ou distúrbio responsivo a cnp |
| WO2011012722A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
| WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
| CN102724967A (zh) | 2009-12-31 | 2012-10-10 | 安龙制药公司 | 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物 |
| WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
| DK2525830T3 (en) | 2010-01-22 | 2016-08-15 | Ascendis Pharma As | DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES |
| EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
| WO2011140393A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled release from macromolecular conjugates |
| JP5964815B2 (ja) | 2010-05-05 | 2016-08-03 | プロリンクス リミテッド ライアビリティ カンパニー | 固体担体からの放出制御薬物 |
| MX338914B (es) | 2010-05-21 | 2016-05-06 | Xl Protein Gmbh | Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos. |
| KR101997939B1 (ko) | 2011-08-12 | 2019-07-08 | 아센디스 파마 에이에스 | 담체-연결된 트레프로스티닐 전구약물 |
| EP3643306A3 (en) | 2011-08-12 | 2020-08-26 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| AU2012296951B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
| HK1198628A1 (en) | 2011-08-12 | 2015-05-22 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| EP2741779A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| CN104379171A (zh) | 2012-04-25 | 2015-02-25 | 第一三共株式会社 | 骨修复促进剂 |
| US20150087688A1 (en) | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| KR20160118264A (ko) | 2014-02-27 | 2016-10-11 | 다이이찌 산쿄 가부시키가이샤 | 스테로이드제 투여로 유발되는 성장 장해에 대한 의약 |
| CA2955569C (en) | 2014-08-06 | 2023-02-14 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| BR112017014560A2 (pt) | 2015-01-09 | 2018-01-02 | Ascendis Pharma Growth Disorders As | profármacos de cnp |
| WO2017100400A2 (en) | 2015-12-08 | 2017-06-15 | Biomarin Pharmaceutical Inc. | Use of c-type natriuretic peptide variants to treat osteoarthritis |
| CN108472380B (zh) | 2016-01-08 | 2022-03-01 | 阿森迪斯药物生长障碍股份有限公司 | 具有增加的nep稳定性的控制释放cnp激动剂 |
| WO2017118698A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| US10835578B2 (en) | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
| WO2017118703A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
| WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| IL259829B2 (en) | 2016-01-08 | 2023-03-01 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr–c binding |
| EP4223309A1 (en) * | 2016-09-29 | 2023-08-09 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release cnp agonists |
| MX2021008708A (es) | 2019-02-11 | 2021-09-21 | Ascendis Pharma Growth Disorders As | Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp). |
-
2017
- 2017-01-05 US US16/067,057 patent/US10835578B2/en active Active
- 2017-01-05 WO PCT/EP2017/050201 patent/WO2017118693A1/en not_active Ceased
- 2017-01-05 CA CA3007976A patent/CA3007976C/en active Active
- 2017-01-05 EP EP17700618.6A patent/EP3400020A1/en active Pending
- 2017-01-05 JP JP2018535304A patent/JP7051686B2/ja active Active
- 2017-01-05 AU AU2017205268A patent/AU2017205268B2/en active Active
- 2017-01-05 MX MX2018008061A patent/MX2018008061A/es unknown
-
2018
- 2018-07-02 ZA ZA2018/04414A patent/ZA201804414B/en unknown
-
2020
- 2020-08-27 US US17/005,272 patent/US20210077584A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/184,561 patent/US11154593B2/en active Active
- 2021-03-01 JP JP2021031431A patent/JP6951597B2/ja active Active
- 2021-11-15 US US17/526,481 patent/US20220296682A1/en not_active Abandoned
-
2022
- 2022-03-01 AU AU2022201416A patent/AU2022201416B2/en active Active
- 2022-03-30 JP JP2022054845A patent/JP7350123B2/ja active Active
-
2023
- 2023-09-12 JP JP2023147381A patent/JP7692454B2/ja active Active
-
2024
- 2024-01-08 US US18/407,324 patent/US20240316153A1/en not_active Abandoned
- 2024-12-19 US US18/986,709 patent/US20250127859A1/en active Pending